First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...